Home LiteratureArticle Details
PMID: 6784805 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

In-vitro venous prostacyclin production, plasma 6-keto-prostaglandin F1 alpha concentrations, and diabetic retinopathy.

British medical journal (Clinical research ed.) ·Vol. 282 ·No. 6272 ·1981-04-18 ·Pages 1259-62

Davis TM, Bown E, Finch DR, Mitchell MD, Turner RC

Abstract

Previous studies have shown that vessels from diabetics produce less prostacyclin in vitro than those from normal controls. To determine whether this decreased production is related to complications elective biopsy of a superficial forearm vein was performed on 12 insulin-dependent male diabetics, six with nil or minimal and six with proliferative retinopathy, and seven male controls. Vein segments from the diabetics and controls produced similar amounts of prostacyclin in vitro (medians 0.11 and 0.19 ng/mg tissue respectively), but the segments from the diabetics with nil or minimal retinopathy produced less than those from the diabetics with proliferative retinopathy (medians 0.09 and 0.18 ng/mg respectively). Preoperative plasma immunoreactive concentrations of 6-keto-prostaglandin F1 alpha were not significantly different between the controls and the diabetics (medians 101 and 116 pg/ml respectively). In a separate study, however, 11 diabetics with duration of disease of over 10 years and nil or minimal retinopathy had significantly lower concentrations than a matched group of 16 with background or proliferative retinopathy (medians 79 and 121 pg/ml respectively). These results do not support an association between reduced prostacyclin production and diabetic retinopathy.

MeSH Terms
6-Ketoprostaglandin F1 alpha Adult Diabetes Mellitus/blood,metabolism Diabetic Retinopathy/blood,metabolism,surgery Epoprostenol/biosynthesis Humans Male Middle Aged Prostaglandins/biosynthesis Prostaglandins F/blood Time Factors Veins/metabolism,surgery
Chemicals
Prostaglandins Prostaglandins F 6-Ketoprostaglandin F1 alpha Epoprostenol
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Davis T M
Bown E
Finch D R
Mitchell M D
Turner R C
References (19)
19 references, click to expand
  1. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study.
    Diabetes. 1974 Feb;23(2):105-11 PMID: 4359625
  2. En face organ culture of vascular endothelium.
    Br J Exp Pathol. 1975 Feb;56(1):8-13 PMID: 1203169
  3. Hyperglycaemia and diabetes mellitus.
    Lancet. 1976 Nov 6;2(7993):1009-12 PMID: 62224
  4. Rapid estimation (2 1/2 hours) of glycosylated haemoglobin for routine purposes.
    Lancet. 1977 Jul 2;2(8027):16 PMID: 69103
  5. [Treatment of diabetes and retinal complications].
    Journ Annu Diabetol Hotel Dieu. 1977;:282-96 PMID: 894870
  6. Decreased vascular prostacyclin in experimental diabetes.
    Life Sci. 1978 Jul 24;23(4):351-5 PMID: 357875
  7. A sensitive radioimmunoassay for 6-keto-prostaglandin F1alpha: preliminary observations on circulating concentrations.
    Prostaglandins Med. 1978 Jul;1(1):13-21 PMID: 102000
  8. Decreased vascular prostacyclin in juvenile-onset diabetes.
    N Engl J Med. 1979 Feb 15;300(7):366-7 PMID: 366410
  9. Vascular prostacyclin may be reduced in diabetes in man.
    Lancet. 1979 Feb 10;1(8111):325-6 PMID: 84977
  10. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls.
    N Engl J Med. 1979 May 17;300(20):1142-7 PMID: 219340
  11. Stability of prostacyclin in plasma.
    Lancet. 1979 Jun 23;1(8130):1352 PMID: 87815
  12. Age-dependent increase in the formation of prostaglandin I2 by intact and homogenised aortae from the developing spontaneously hypertensive rat.
    Biochim Biophys Acta. 1979 Jul 27;574(1):177-81 PMID: 383156
  13. Prostacyclin and thromboxane metabolites in diabetes.
    Lancet. 1979 Oct 13;2(8146):789-90 PMID: 90875
  14. Circulating prostacyclin may be reduced in diabetes.
    Lancet. 1979 Dec 22-29;2(8156-8157):1365 PMID: 92700
  15. Is prostacyclin a physiologically important circulating anti-platelet agent?
    Nature. 1980 Jan 10;283(5743):194-5 PMID: 6243178
  16. Plasma 6-keto-PGF1 alpha concentrations and diabetic retinopathy.
    Lancet. 1980 Feb 16;1(8164):373 PMID: 6101831
  17. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation.
    Lancet. 1977 Jan 1;1(8001):18-20 PMID: 63657
  18. Effect of insulin treatment on prostacyclin in experimental diabetes.
    Diabetologia. 1980 Jan;18(1):65-8 PMID: 6988267
  19. Increased prostacyclin release from perfused hearts of acutely diabetic rats.
    Diabetologia. 1980 May;18(5):391-4 PMID: 7000593
Article Info
Journal
British medical journal (Clinical research ed.)
Abbr.
Br Med J (Clin Res Ed)
ISSN
0267-0623
Published
1981-04-18
Pages
1259-62
Language
English
Region
England
NLM ID
8302911
PMCID
PMC1505380
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]